OncoMatch/Clinical Trials/NCT07410494
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Is NCT07410494 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including EB-SELECT Single-Target CAR-NK Cells and Dual-Target Antigen-Selected CAR-NK for cancer.
Treatment: EB-SELECT Single-Target CAR-NK Cells · Dual-Target Antigen-Selected CAR-NK — This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors. The CAR target antigen is selected for each participant after tumor profiling using a tissue biopsy and/or liquid biopsy. Participants will receive either a single-target or dual-target CAR-NK product based on the antigen profile.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Prostate Cancer
Pancreatic Cancer
Ovarian Cancer
Glioblastoma
Melanoma
Acute Myeloid Leukemia
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Multiple Myeloma
Hepatocellular Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard therapy — relapsed/refractory after standard therapy, or no standard therapy available
relapsed/refractory after standard therapy, or no standard therapy available
Cannot have received: gene-modified cellular therapy (CAR-T, CAR-NK)
Exception: allowed after defined washout period
Prior treatment with gene-modified cellular therapy (e.g., CAR-T, CAR-NK) within a defined washout period
Lab requirements
Blood counts
within protocol-defined limits
Kidney function
within protocol-defined limits
Liver function
within protocol-defined limits
Cardiac function
within protocol-defined limits
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify